Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Line drawing of babies.

Professor Andi Roy leads the Childhood Leukaemia research group at the MRC Weatherall Institute of Molecular Medicine, and is a member of Oxford Centre for Haematology.

Despite improvements in overall survival over the last 40 years, cancer remains the leading cause of death by disease in children and young people (aged 1-24) in the UK. The Cancer Research UK–Children with Cancer UK Innovation Awards will allow researchers to gain a better understanding of cancer in children, which they hope will lead to the development of better and less toxic treatments.

Professor Roy's group aims to develop a new way to treat a type of acute lymphoblastic leukaemia (ALL), known as Mixed Lineage Leukaemia (MLL) gene rearranged infant ALL (MLLr-iALL), which currently has a particularly low survival rate.  CAR T-cell therapy, which uses modified versions of a patient’s T cells to attack their cancer, is often used to treat leukaemia. But using this potentially life-saving treatment in very young patients is limited, because it’s very difficult to obtain T cells from them, as these patients have already gone through intensive chemotherapy and are often immunocompromised.

Read the full story on the Radcliffe Department of Medicine website.

Similar stories

Oxford University academics recognised in Queen’s Birthday Honours

The pioneering work of members of the University, including research into tackling the Coronavirus pandemic, has been recognised in The Queen's Birthday Honours List.

Two Oxford Professors elected as EMBO Members

Professor Robert Klose and Professor Ervin Fodor are two of 64 life scientists to be elected to The European Molecular Biology Organization (EMBO).

Scientists make DNA breakthrough which could identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine at Oxford University have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

AI endoscopy enables 3D surface measurements of pre-cancerous condition in oesophagus

Clinicians and engineers in Oxford have begun using artificial intelligence alongside endoscopy to get more accurate readings of the pre-cancerous condition Barrett’s oesophagus and so determine patients most at risk of developing cancer.

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

New Head of the Department of Psychiatry – Professor Belinda Lennox

Professor Belinda Lennox has been welcomed to the role of Head of the Department of Psychiatry at the University of Oxford and will take over leadership in October 2021.